Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-Aventis receives expanded Lovenox approval
During this kind of heart attack, known as acute ST-segment elevation myocardial infarction (STEMI), an artery is generally completely blocked by a blood clot for long enough to
During this kind of heart attack, known as acute ST-segment elevation myocardial infarction (STEMI), an artery is generally completely blocked by a blood clot for long enough to
Amitiza (lubiprostone) is marketed in the US for chronic idiopathic constipation, and the new study compared Amitiza with placebo in two groups of patients with irritable bowel syndrome
A phase I clinical study for injectable, subcutaneous (SC) Belerofon began in Texas, US last month and the results of the trial are expected to be completed in
On May 18, 2007 the FDA granted final approval to Teva of its amlodipine besylate/benazepril products in 2.5mg/10mg, 5mg/10mg; 5mg/20mg and 10mg/20mg dosage strengths, AB rated to Novartis’
The US regulator has approved the combination in patients with multiple myeloma who have not received Velcade previously, but have been treated with at least one prior therapy.
Researchers at the California Institute of Technology have been using small interfering RNA (siRNA), sometimes known as silencing RNA, to “silence” specific genes that are implicated in certain
The extended-release tablets are a generic version of UK pharmaceutical company AstraZeneca’s Toprol-XL treatment. KV said that as it was the first to file the application with the
The FDA has issued an approvable letter for Mircera for the treatment of anemia associated with chronic renal failure, and Roche expects the label to be finalized after
The offer accounts for less that 0.13% of all Amgen’s outstanding shares. Amgen said that it “is not associated in any way with TRC, this mini-tender offer or
Curis said that Ortho Biotech will cease its development efforts on the BMP-7 program and the agreement will now terminate on August 16, 2007. Daniel Passeri, president and